Last reviewed · How we verify
Doptelet Pill
Doptelet (avatrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by binding to the TPO receptor on bone marrow megakaryocytes.
Doptelet (avatrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by binding to the TPO receptor on bone marrow megakaryocytes. Used for Thrombocytopenia in patients with chronic liver disease undergoing scheduled invasive procedures, Immune thrombocytopenia (ITP).
At a glance
| Generic name | Doptelet Pill |
|---|---|
| Sponsor | Hvidovre University Hospital |
| Drug class | Thrombopoietin receptor agonist |
| Target | TPO receptor (TPOR/MPL) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Avatrombopag activates the thrombopoietin (TPO) signaling pathway, which promotes megakaryocyte proliferation and maturation, leading to increased platelet production. This mechanism helps restore platelet counts in patients with thrombocytopenia by enhancing endogenous thrombopoiesis without requiring exogenous TPO administration.
Approved indications
- Thrombocytopenia in patients with chronic liver disease undergoing scheduled invasive procedures
- Immune thrombocytopenia (ITP)
Common side effects
- Headache
- Nausea
- Diarrhea
- Abdominal pain
- Thromboembolic events
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Doptelet Pill CI brief — competitive landscape report
- Doptelet Pill updates RSS · CI watch RSS
- Hvidovre University Hospital portfolio CI